Certis Oncology Solutions Announces Presentation of Abstract at Society for Immunotherapy of Cancer Annual Meeting


Presentation to highlight importance of study design in evaluating anti-tumor effects of immunotherapies in preclinical models

 

San Diego, Calif.November 1, 2023 – Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in San Diego, Calif. November 1-5, 2023.

 

“The growing use of immunotherapies to treat cancers must be met with a re-examination of the preclinical research methods used to study new therapeutics in development,” said Peter Ellman, CEO of Certis Oncology Solutions. “Our research illustrates the variation of results that can be achieved using different types of preclinical mouse models to study immunotherapy compounds and shows the importance of selecting models that are best capable of recapitulating the complexities of the human immune system and tumor microenvironment.”

 

Certis scientists will discuss results from a study which compared differences in gene expression influenced by the tumor microenvironment in humanized patient-derived xenograft models of cancers. The study sought to demonstrate differences in overall immune response and pharmacological outcome when comparing results from PDX models with subcutaneous and orthotopic implantation sites.

 

Abstract Number 1453: "In Vivo Tumor Implantation Site Exhibits Differential Immune Response in Solid Tumors"

Poster Session: Friday, Nov. 3, 2023, 9 am–7pm

Abstract: Historically, patient-derived xenograft (PDX) modeling involves subcutaneous implantation which minimally represents the actual human tumor site, as opposed to orthotopic implantation (O-PDX) which more accurately reflects the local tumor microenvironment. This study compared both types of PDX models as well as humanized PDX models developed using peripheral blood mononuclear cells (PBMC), to demonstrate the differences in the effectiveness of each model. The research showed significant pathways altered between the models, including immunoregulatory interactions between the PDX and O-PDX models, and showed differences in presence of tumor infiltrating lymphocytes as well as differential in vivo efficacy and immunophenotypes in the PBMC humanized mice treated with checkpoint inhibiting compounds.

Download Poster

About Certis Oncology Solutions

Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies.

###

 

MEDIA CONTACT

Certis Oncology Solutions

Kristein King

kking@certisoncology.com

573-818-4528

Back to Feed


Share This